Artículos de revistas
Dexamethasone/povidone Eye Drops Versus Artificial Tears For Treatment Of Presumed Viral Conjunctivitis: A Randomized Clinical Trial
Registration in:
Dexamethasone/povidone Eye Drops Versus Artificial Tears For Treatment Of Presumed Viral Conjunctivitis: A Randomized Clinical Trial. Taylor & Francis Inc, v. 40, p. 870-877 2015.
0271-3683
WOS:000361327200002
10.3109/02713683.2014.964419
Author
Pacheco Pinto
Roberto Damian; Cavalcanti Lira
Rodrigo Pessoa; Abe
Ricardo Yuji; Zacchia
Rafael Santos; Fernandes Felix
Joao Paulo; Fernandes Pereira
Andre Venancio; Leite Arieta
Carlos Eduardo; de Castro
Rosane Silvestre; Alves Bonon
Sandra Helena
Institutions
Abstract
Purpose: To determine whether topical dexamethasone 0.1%/povidone-iodine 0.4% reduces the duration of presumed viral conjunctivitis better than artificial tears and whether the treatment relieves the symptoms of this disease. Methods: Randomized, masked and controlled trial. One-hundred twenty-two patients with a clinical diagnosis of presumed viral conjunctivitis were randomized to either the treatment group or the control group. Physicians and patients were masked to the treatment. Swabs were taken from the conjunctival fornix for adenovirus PCR analyses. Patients in the treatment group received topical dexamethasone 0.1%/povidone-iodine 0.4% eye drops four times daily, and patients in the placebo group received artificial tears four times daily, both for seven days. Symptoms were recorded on the day of recruitment and at the time of a follow-up examination 5, 10 and 30 d later. The main outcome was duration of the disease. The others outcomes were overall discomfort, itching, foreign body sensation, tearing, redness, eyelid swelling, side effects of the eye drops, intraocular pressure and the incidence of subepithelial corneal infiltrates. Results: There was no statistically significant difference between the treatment group and the control group in terms of the patients' symptoms, intraocular pressure and incidence of subepithelial cornea infiltrates during the entire follow-up period. Patients of the treatment group reported more stinging (p<0.001) and a shorter conjunctivitis duration (9.4 +/- 4.6 d in the dexamethasone 0.1%/povidone-iodine 0.4% group versus 11.8 +/- 4.9 d in the artificial tears group, p = 0.009). Conclusions: The use of topical dexamethasone 0.1%/povidone-iodine 0.4% eye drops four times daily appears to reduce the duration of conjunctivitis, although it causes more stinging than artificial tears. 40 9
870 877 Ophthalmos S/A, Sao Paulo, Brazil